Document is current
Any future updates will be listed below
-
Authors
Lachiewicz, Ave M. https://orcid.org/0000-0002-2934-3088
Stackhouse, Tracy M. https://orcid.org/0000-0001-6540-803X
Burgess, Kristin
Burgess, Debra
Andrews, Howard F. https://orcid.org/0000-0002-7726-0551
Choo, Tse-Hwei https://orcid.org/0000-0001-5068-9799
Kaufmann, Walter E. https://orcid.org/0000-0002-8561-8453
Kidd, Sharon A. https://orcid.org/0000-0002-7562-8682
-
Funding
Funding for this research was provided by:
Centers for Disease Control and Prevention (U01DD000231)
Centers for Disease Control and Prevention (U01DD000753)
Centers for Disease Control and Prevention (U01DD001189)
North Carolina Civitans East
Don Bower Fund
Knights of Columbus Operation Lamb, Inc.
- License Information
-
More Information
Article History
Accepted: 6 September 2023
First Online: 16 October 2023
Declarations
:
: WEK: Chief Scientific Officer, Anavex Life Sciences Corp.; consultant to Tetra Therapeutics. The other co-authors have no competing interests to declare.
